HIV type 1 cervicovaginal reservoirs in the era of HAART

AIDS Research and Human Retroviruses

Volumn 21, Issue 8, 2005, Pages 714-718

  Nunnari, Giuseppe ^a   Sullivan, Julie ^a   Xu, Yan ^a   Nyirjesy, Paul ^a   Kulkosky, Joseph ^a   Cavert, Winston ^b   Frank, Ian ^c   Pomerantz, Roger J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; RITONAVIR; STAVUDINE; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LAVAGE; NONHUMAN; PRIORITY JOURNAL; PROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAFE SEX; SEXUAL TRANSMISSION; UTERINE CERVIX; UTERINE ENDOCERVIX; VIROGENESIS; VIRUS DETECTION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CERVIX UTERI; FEMALE; HIV-1; HUMANS; RNA, VIRAL; VAGINA;

EID: 24344495217     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2005.21.714     Document Type: Article

References (24)

1. Palella FJ, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
2. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725-733.
3. Pomerantz RJ: Residual HIV-1 infection during antiretroviral therapy: The challenge of viral persistence. AIDS 2001;15:1201-1211.
4. Gupta P, Mellors J, Kingsley L, et al.: High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. J Virol 1997;71:6271-6275.
5. Zhang H, Dornadula G, Beumont M, et al.: Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med 1998;339:1803-1809.
6. Cu-Uvin S, Caliendo AM, Reinert S, et al.: Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000; 14:415-421.
7. Coombs RW, Reichelderfer PS, and Landay AL: Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS 2003;17:455-480.
8. Nunnari G, Otero M, Dornadula G, et al.: Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: Latency without on-going cellular infections. AIDS 2002;16:39-45.
9. Fiore JR, Suligoi B, Saracino A, et al.: Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS 2003;17:2169-2176.
10. Kovacs A, Wasserman SS, Burns D, et al.: DATRI Study Group; and the WIHS Study Group: Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001;358:1593-1601.
11. Chun TW, Carruth L, Finzi D, et al.: Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997;387:183-188.
12. Dornadula G, Zhang H, VanUitert B, et al.: Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999;282:1627-1632.
13. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-1300.
14. Sonza S, Mutimer HP, Oelrichs R, et al.: Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy. AIDS 2001;15:17-22.
15. Valentin A, Rosati M, Patenaude DJ, et al.: Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci USA 2002;99:7015-7020.
16. Saha K, Zhang J, Gupta A, Dave R, Yimen M, and Zerhouni B: Isolation of primary HIV-1 that targets CD8+ T lymphocytes using CD8 as a receptor. Nat Med 2001;7:65-72.
17. Pomerantz RJ, de la Monte SM, Donegan SP, et al.: Human immunodeficiency virus (HIV) infection of the uterine cervix. Ann Intern Med 1988;108:321-327.
18. Shaheen F, Sison AV, McIntosh L, Mukhtar M, and Pomerantz RJ: Analysis of HIV-1 in the cervicovaginal secretions and blood of pregnant and nonpregnant women. J Hum Virol 1999;2: 154-166.
19. Wu Z, Chen Z, and Phillips DM: Human genital epithelial cells capture cell-free human immunodeficiency virus type 1 and transmit the virus to CD4+ cells: Implications for mechanisms of sexual transmission. J Infect Dis 2003;188:1473-1482.
20. Asin SN, Wildt-Perinic D, Mason SI, Howell AL, Wira CR, and Fanger MW: Human immunodeficiency virus type 1 infection of human uterine epithelial cells: Viral shedding and cell contact-mediated infectivity. J Infect Dis 2003;187:1522-1533.
21. Kemal KS, Foley B, Burger H, et al.: HIV-1 in genital tract and plasma of women: Compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci USA 2003; 100:12972-12977.
22. De Pasquale MP, Leigh Brown AJ, Uvin SC, et al.: Differences in HIV-1 pol sequences from female genital tract and blood during antiretroviral therapy. J Acquir Immune Defic Syndr 2003;34: 37-44.
23. Kulkosky J, Nunnari G, Otero M, et al.: Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J Infect Dis 2002;186: 1403-1411.
24. Dornadula G, Nunnari G, Vanella M, et al.: Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressively highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups. J Infect Dis 2001;183:1682-1687.